These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 3252045)
1. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. Abernethy DR; Egan JM; Dickinson TH; Carrum G J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045 [TBL] [Abstract][Full Text] [Related]
2. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state. Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489 [TBL] [Abstract][Full Text] [Related]
3. The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione. Ohashi K; Sakamoto K; Sudo T; Tateishi T; Harada K; Fujimura A; Ebihara A; Tanaka E J Clin Pharmacol; 1991 Dec; 31(12):1132-6. PubMed ID: 1761736 [TBL] [Abstract][Full Text] [Related]
4. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene. Groen K; Breimer DD; van Bezooijen CF Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725 [TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of warfarin metabolism by diltiazem in humans. Abernethy DR; Kaminsky LS; Dickinson TH J Pharmacol Exp Ther; 1991 Apr; 257(1):411-5. PubMed ID: 2020000 [TBL] [Abstract][Full Text] [Related]
6. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates. Sakai H; Kobayashi S; Hamada K; Iida S; Akita H; Tanaka E; Uchida E; Yasuhara H Br J Clin Pharmacol; 1991 Mar; 31(3):353-5. PubMed ID: 2054276 [TBL] [Abstract][Full Text] [Related]
8. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486 [TBL] [Abstract][Full Text] [Related]
9. The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. Bottorff MB; Lalonde RL; Kazierad DJ; Hoon TJ; Tsiu SJ; Mirvis DM Pharmacotherapy; 1989; 9(5):315-21. PubMed ID: 2510135 [TBL] [Abstract][Full Text] [Related]
10. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715 [TBL] [Abstract][Full Text] [Related]
11. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine. Carrum G; Egan JM; Abernethy DR Clin Pharmacol Ther; 1986 Aug; 40(2):140-3. PubMed ID: 3731677 [TBL] [Abstract][Full Text] [Related]
12. Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats. Teunissen MW; Van Graft M; Vermeulen NP; Breimer DD Xenobiotica; 1983 Aug; 13(8):497-502. PubMed ID: 6649682 [TBL] [Abstract][Full Text] [Related]
13. Effect of nifedipine on antipyrine and theophylline disposition. Adebayo GI; Mabadeje AF Biopharm Drug Dispos; 1990 Mar; 11(2):157-64. PubMed ID: 2183884 [TBL] [Abstract][Full Text] [Related]
14. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat. Adedoyin A; Aarons L; Houston JB Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749 [TBL] [Abstract][Full Text] [Related]
15. The influence of dietary restriction on the metabolism of theophylline and antipyrine in the ageing female BN/BiRij rat. Groen K; Breimer DD; Brouwer A; Schijff G; Jansen EJ; van Bezooijen CF J Pharmacol Exp Ther; 1995 Jul; 274(1):143-7. PubMed ID: 7616391 [TBL] [Abstract][Full Text] [Related]
16. Incidence of a subclinical fascioliasis on antipyrine clearance and metabolite excretion in sheep. Tufenkji AE; Alvinerie M; Pineau T; Boulard C; Galtier P Xenobiotica; 1988 Apr; 18(4):357-64. PubMed ID: 3400265 [TBL] [Abstract][Full Text] [Related]
17. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978 [TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances. Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580 [TBL] [Abstract][Full Text] [Related]
19. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man. Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432 [TBL] [Abstract][Full Text] [Related]
20. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]